HOXB7 and lung markers in pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This study looks at a protein called HOXB7 and other markers in lung tissue and blood to better understand pulmonary fibrosis. It may help researchers find new ways to diagnose or treat the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You have a suspected diagnosis of pulmonary fibrosis, a lung scarring disease.
- Fresh lung tissue from a biopsy or lung surgery must be available for testing.
- You must sign a consent form allowing the research use of your tissue and health data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
This study looks for genetic causes of pulmonary fibrosis that runs in families. You and your affected family member(s) would provide blood samples and health info to help researchers understand why lung scarring happens.
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
This study collects and stores health information and possibly blood samples from people being evaluated for pulmonary hypertension or related autoimmune conditions. It helps researchers learn more about these illnesses and may support future studies.
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
Hear when a new Fibrosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.